AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1 - 37 (Canceled).

38. (Currently Amended): The method of Claim ~~37~~70, wherein the solution is an aqueous-ethanolic solution.

39. (Withdrawn-Currently Amended): The method of Claim ~~37~~70, wherein step 1) is preceded by a step 0) which comprises: applying to a skin area of an individual a solution of lactic acid at a concentration of between 2% and 10% by weight relative to the total weight of the composition.

40. (Withdrawn): The method of Claim 39, wherein the solution of lactic acid has a concentration of 10% by weight relative to the total weight of the composition.

41. (Currently Amended): The method of Claim ~~37~~70, wherein the concentration of stimulant is between 5×10^{-5}% and 5×10^{-4}% by weight relative to the total weight of the composition.

42. (Original): The method of Claim 41, wherein the concentration of the stimulant is 1×10^{-4}% by weight relative to the total weight of the composition.

43. (Currently Amended): The method of Claim ~~37~~70, wherein step 1) comprises between 1 and 3 applications of the aqueous or aqueous-alcoholic solution to the skin area of the individual.

44. (Previously Presented): The method of Claim 43, wherein step 1) comprises 3 applications of the aqueous or aqueous-alcoholic solution to the skin area of the individual.

45. (Withdrawn): The method of Claim 39, wherein step 0) comprises between 1 and 10 applications of lactic acid solution.

46. (Withdrawn): The method of Claim 45, wherein step 0) comprises 10 applications of lactic acid solution.

47. (Currently Amended): The method of Claims ~~37~~70, wherein the skin area is the bend of the arm, the lobe of the ear, the posterior face of the pinna of the ear, the face, the wing of the nose, the nasogenial sulcus or the point of the lower maxillary.

48. (Original): The method of Claim 38, wherein the aqueous-ethanolic solution comprises from 1% to 50% of ethanol in water.

49. (Original): The method of Claim 48, wherein the aqueous-ethanolic solution comprises from 5% to 20% ethanol in water.

50. (Original): The method of Claim 48, wherein the aqueous-ethanolic solution comprises from 8% to 15% ethanol in water.

51. (Original): The method of Claim 48, wherein the aqueous-ethanolic solution comprises 10% ethanol in water.

52. (Currently Amended): The method of Claim ~~37~~70, wherein the capsaicinoid is a natural capsaicinoid, a synthetic capsaicinoid, a synthetic extract or a plant extract.

53.-63. (Canceled).

64. (Withdrawn): A kit comprising: a plurality of containers each holding increasing concentrations of a peripheral nervous system stimulant in combination with a physiologically acceptable vehicle; at least one container which holds the vehicle alone; and a single applicator system, wherein the at least one container holds a concentration of the peripheral nervous system stimulant of between 1×10^{-6}% and 1×10^{-4}% by weight relative to the total weight of the composition.

65. (Withdrawn): The kit according to Claim 64, wherein the single applicator system is a cotton bud.

66. (Withdrawn): The kit according to Claim 64, wherein the concentration of the peripheral nervous system stimulant is between 3×10^{-6}% and 6×10^{-5}% by weight relative to the total weight of the composition.

67. (Withdrawn): The kit according to Claim 64, wherein the concentration of the peripheral nervous system stimulant is $3.16 \times 10^{-5}\%$ by weight relative to the total weight of the composition.

68.-69 (Canceled)

70. (Previously Presented): A non-therapeutic method of evaluating the level of skin neurosensitivity of an adult individual to a capsaicinoid, the method comprising: 1) applying to a skin area of the individual a first composition comprising a physiologically acceptable vehicle that is an aqueous or aqueous-alcoholic solution and a peripheral nervous system stimulant that is a capsaicinoid, the concentration of the stimulant being between $1 \times 10^{-6}\%$ and $1 \times 10^{-4}\%$ by weight relative to the total weight of the composition; 2) recording whether the individual detects an unattractive sensation; 3) if no sensation is detected by the individual, repeating steps 1) and 2) with a composition containing a higher concentration of the same stimulant until the individual detects an unattractive sensation or until a composition containing a maximum concentration value of the stimulant is applied; and 4) deducing, from the last concentration applied, information regarding the skin neurosensitivity of the individual,

wherein the unattractive sensation is at least one selected from the group consisting of stinging, pins and needles, itching, pruritus, hotness and pulling.

71. (Previously Presented): The method of Claim 70, wherein in step 3) the concentration of stimulant in the composition is such that the application of the composition is unlikely to give rise to painful unattractive sensations in the individual.

72. (Previously Presented): The method of Claim 70, wherein in step 3) the concentration of stimulant increases by a factor of between 1.5 and 10.

73. (Previously Presented): The method of Claim 72, wherein the concentration of stimulant increases by a factor of between 2 and 5.

74. (Previously Presented): The method of Claim 72, wherein the concentration increases by a factor of the square root of 10.

75. (Previously Presented): The method of Claim 70, wherein the concentration of stimulant in the first composition applied in step 1) is between $3 \times 10^{-6}\%$ and $6 \times 10^{-5}\%$.

76. (Previously Presented): The method of Claim 75, wherein the concentration of stimulant in the first composition applied in step 1) is $3.16 \times 10^{-5}\%$.

77. (Previously Presented): The method of Claim 70, wherein the solution is an aqueous-alcoholic solution with an alcohol content of less than 50%.

78.-79 (Canceled)

80. (Previously Presented): The method of Claim 70, wherein the skin area is the bend of the arm, the lobe of the ear, the posterior face of the pinna of the ear, the face, the wing of the nose, the nasogenial sulcus or the point of the lower maxillary.

81. (Previously Presented): The method of Claim 80, wherein the skin area is the wing of the nose.

82. (Previously Presented): The method of Claim 70, wherein physiologically acceptable vehicle is an aqueous-ethanolic solution containing from 1% to 50% of ethanol in water.

83. (Previously Presented): The method of Claim 82, wherein the aqueous-ethanolic solution contains from 5% to 20% ethanol in water.

84. (Previously Presented): The method of Claim 82, wherein the aqueous-ethanolic solution contains from 8% to 15% ethanol in water.

85. (Previously Presented): The method of Claim 82, wherein the aqueous-ethanolic solution contains 10% of ethanol in water.

86. (Previously Presented): The method of Claim 70, wherein step 1) is preceded by prior application to a skin area of a composition comprising the vehicle without stimulant.

87. (Previously Presented): A non-therapeutic method of evaluating the level of skin neurosensitivity of an adult individual to a capsaicinoid, the method comprising: a) applying a composition comprising a physiologically acceptable vehicle that is an aqueous or aqueous-alcoholic solution to a skin area of a subject; b) recording whether the subject perceived an

unattractive sensation on the skin area having received the vehicle; c) if so, stopping the test; if not, applying to a skin area, optionally to the same area having received the vehicle previously, the same vehicle containing a peripheral nervous system stimulant that is a capsaicinoid at a concentration of between 1×10^{-6}% and 1×10^{-4}%; d) recording whether the subject perceived an unattractive sensation on the skin area having received the composition containing the stimulant; e) if so, recording the concentration of stimulant and stopping the test; if not, increasing the concentration of stimulant by a factor of between 1.5 and 10, and repeating steps c) to e) n times, where n is between 1 and 10,

wherein the unattractive sensation is at least one selected from the group consisting of stinging, pins and needles, itching, pruritus, hotness and pulling.

88. (Previously Presented): The method of Claim 87, further comprising waiting for 30 to 360 seconds at least one of after step a) and before step b) and after step c) and before step d).

89. (Previously Presented): The method of Claim 88, wherein the waiting is for 120 to 200 seconds.

90. (Previously Presented): The method of Claim 88, wherein the waiting is for 180 seconds.

91. (Previously Presented): The method of Claim 87, wherein step a) is preceded by prior application to a skin area and to its area on the opposite side of a composition comprising the vehicle without stimulant.

92. (Previously Presented): A non-therapeutic method of evaluating the level of skin neurosensitivity of an adult individual to a capsaicinoid, the method comprising a) applying a composition comprising a physiologically acceptable vehicle that is an aqueous or aqueous-alcoholic solution to a skin area and to its area on the opposite side; b) recording whether the subject perceived an unattractive sensation on at least one of the areas having received the vehicle; c) if so, stopping the test; if not, applying to a skin area, the same vehicle containing a peripheral nervous system stimulant that is a capsaicinoid at concentration of between 1×10^{-6}% and 1×10^{-4}%; and applying the same vehicle to the area on the opposite side; d) recording whether the subject perceived a discriminating unattractive sensation on the skin area having received the vehicle containing the stimulant in relation to the skin area on the opposite side; and e) if so, recording the concentration of stimulant and stopping the test; if not, increasing the concentration of stimulant by a factor of between 1.5 and 10, and repeating steps c) to e) n times, where n is between 1 and 10,

wherein the unattractive sensation is at least one selected from the group consisting of stinging, pins and needles, itching, pruritus, hotness and pul
ling.

93. (Previously Presented): The method of Claim 92, further comprising waiting for 30 to 360 seconds at least one of after step a) and before step b) and after step c) and before step d).

94. (Previously Presented): The method of Claim 93, wherein the waiting is for 120 to 200 seconds.

95. (Previously Presented): The method of Claim 93, wherein the waiting is for 180 seconds.